Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (9209)	6/5/1998 2:05:00 AM
From: VLAD	Respond to of 23519

The Good Ole Days: SI Inbox \| Folders Bookmarks \| People Hot \| New Subjects Options \| Profile Talk : Biotechnology : VIVUS 1997/1998 \| Previous \| Next \| Respond \| Silicon Investor Home Page To: Baja Don (1512 ) From: Sonki Sunday, Oct 26 1997 1:45AM ET Reply # of 9208 Robert M. Cohen & Co. Reiterates Rating on Vivus; Analyst Continues Speculative Buy and $50-1/2 Price Target GREAT NECK, N.Y., Oct. 24 /PRNewswire/ -- Robert M. Cohen & Company analyst Keith R. Bossey reiterated his speculative buy rating on Vivus, Inc. (Nasdaq:VVUS) and continued his 6-month price target of $50-1/2 following an announcement that Pfizer (NYSE:PFE) may introduce a competing impotence drug. Bossey noted, ''While we admit that in most cases competition is unfavorable, Pfizer's entry into the impotence market may expand the market for all involved. Although Pfizer's Viagra may be deemed easier to use, we feel Vivus' on demand product will retain its current favorable market position.'' Bossey added that the recent weakness in Vivus' stock has presented an excellent buying opportunity, and the company's earnings performance over the last three quarters has silenced substantial skepticism surrounding the stock. \| Previous \| Next \| Respond \| View reply to this message Quotes - 100-Day Chart - News - Profile - Earnings - Discussion - Biotechnology View SubjectMarks Bookmark this Subject Vivus (NASDAQ: VVUS) Date: Jun 04 Last Trade 6 5/16 Change - 3/4 (-10.62%) Bid 6 5/16 Ask 6 11/32 Volume 03,074,3000 Prev.Close 7 1/16 Open 6 7/8 Day Range 6 1/8 - 7 00 Last Tick 0Down0 Avg.Volume 01,937,8000 Discussion \| People \| MetaCrawler Subject Titles Only Full-Text Messages with Links Send questions and feedback to webmistress@techstocks.com Terms of Use

To: Mkilloran who wrote (9209)	6/5/1998 2:33:00 AM
From: bigg e	Respond to of 23519

mk...Believe the international estimates were leaning to the conservative side. It seems that with further approvals the numbers could increase. But with pending VIAGRA approval on the international front and seeing the decayed script data here following FDA approval it's hard to say. As to milestone payments I'll have to dig a little deeper to see what may be pending. Look for possible milestone type payments potentially on the domestic front if outside marketing/license agreements are achieved. Domestically scripts are forecast to turn upwards in next 1-3 weeks but this is an unknown. As far as domestic sales forecast again hard to call. Will see what I can find out. Another bit of info I heard. The efficacy issue is a past issue and the negative reports are suspect. Supposedly there was another study conducted with 350 ED Patients in which the data was very encouraging. I do not believe this data was presented at the AUA meetings. Will try to get more definitive info on this issue. And on the rumor front supposedly someone big is adding to the portfolio. If the rumor prove's true you'll know it.

To: Mkilloran who wrote (9209)	6/5/1998 8:14:00 PM
From: bigg e	Respond to of 23519

mk...Reference the 350 patient study I spoke of. Apparently the data was presented at the AUA conference but was not reported by the media.The media can be very selective. The study was in a clinical environment conducted by Dr.Andrew G aye and found a 70% success rate. On the other questions still digging for info. Should know more by next week. Also word on some insider buying starting to surface. And again, the whisper of a respected investor accumulating is floating about. Time will tell.